Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Guido Tricot to Multiple Myeloma

This is a "connection" page, showing publications Guido Tricot has written about Multiple Myeloma.

 
Connection Strength
  
 
 
9.119
  
  1. Strouse C, Mott SL, Smith BJ, Magalhaes-Silverman M, Farooq U, Zhan F, Jethava Y, Tricot G. Transplant conditioning with bortezomib, thalidomide, and melphalan and intensive 2 year post-transplant therapy for multiple myeloma in older patients. Bone Marrow Transplant. 2024 01; 59(1):128-130.
    View in: PubMed
    Score: 0.311
  2. Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot G. A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. Cell Transplant. 2019 Dec; 28(12):1624-1631.
    View in: PubMed
    Score: 0.236
  3. Jethava YS, Barlogie B, Tricot GJ. Drug Combinations with Transplantation for Myeloma. N Engl J Med. 2017 07 06; 377(1):91-2.
    View in: PubMed
    Score: 0.201
  4. Abbi KK, Silverman M, Farooq U, Tricot A, Dozeman L, Nadiminti K, Krasowski MD, Tricot GJ. Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma. Br J Haematol. 2016 08; 174(4):536-40.
    View in: PubMed
    Score: 0.186
  5. Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G. Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget. 2015 Dec 01; 6(38):40496-506.
    View in: PubMed
    Score: 0.180
  6. Hansson M, Gimsing P, Badros A, Niskanen TM, Nahi H, Offner F, Salomo M, Sonesson E, Mau-Sorensen M, Stenberg Y, Sundberg A, Teige I, Van Droogenbroeck J, Wichert S, Zangari M, Frendeus B, Korsgren M, Poelman M, Tricot G. A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2015 Jun 15; 21(12):2730-6.
    View in: PubMed
    Score: 0.171
  7. Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H, Zhou W, Zhou Y, Das S, Gu Z, Levasseur D, Zhan F, Tricot G. RARa2 expression confers myeloma stem cell features. Blood. 2013 Aug 22; 122(8):1437-47.
    View in: PubMed
    Score: 0.153
  8. Zangari M, Terpos E, Zhan F, Tricot G. Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev. 2012 Dec; 38(8):968-80.
    View in: PubMed
    Score: 0.138
  9. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7.
    View in: PubMed
    Score: 0.132
  10. Zangari M, Fink L, Zhan F, Tricot G. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):228-36.
    View in: PubMed
    Score: 0.131
  11. Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S, Suva LJ, Gruenwald JM, Kern S, Zhan F, Esseltine D, Tricot G. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 2011 Feb; 96(2):333-6.
    View in: PubMed
    Score: 0.126
  12. Tricot G, Kern SE, Barlogie B. Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009 Jul 01; 101(13):964-6; author reply 966-7.
    View in: PubMed
    Score: 0.115
  13. Tricot G, Zangari M, Sorasio R, Bruno B. Evolving indications for hematopoietic stem cell transplantation in multiple myeloma and other plasma cell disorders. Cancer Treat Res. 2009; 144:317-55.
    View in: PubMed
    Score: 0.112
  14. Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica. 2008 Nov; 93(11):1739-42.
    View in: PubMed
    Score: 0.109
  15. Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis. 2007 Oct; 18(7):595-8.
    View in: PubMed
    Score: 0.102
  16. Zangari M, Esseltine D, Cavallo F, Neuwirth R, Elice F, Burns MJ, Yaccoby S, Richardson P, Sonneveld P, Tricot G. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol. 2007 Sep; 82(9):831-3.
    View in: PubMed
    Score: 0.102
  17. Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G. Hyperammonemia and encephalopathy in patients with multiple myeloma. Am J Hematol. 2007 May; 82(5):414-5.
    View in: PubMed
    Score: 0.099
  18. Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Rev Anticancer Ther. 2007 Mar; 7(3):307-15.
    View in: PubMed
    Score: 0.098
  19. Tricot GJ. What is the significance of molecular remission in multiple myeloma? Clin Adv Hematol Oncol. 2007 Feb; 5(2):91-5.
    View in: PubMed
    Score: 0.098
  20. Zangari M, Cavallo F, Tricot G. Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma. Curr Pharm Biotechnol. 2006 Dec; 7(6):449-53.
    View in: PubMed
    Score: 0.097
  21. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma. 2006 Sep; 7(2):109-14.
    View in: PubMed
    Score: 0.095
  22. Talamo G, Cavallo F, Zangari M, Barlogie B, Lee CK, Pineda-Roman M, Kiwan E, Krishna S, Tricot G. Clinical and biological features of multiple myeloma involving the gastrointestinal system. Haematologica. 2006 Jul; 91(7):964-7.
    View in: PubMed
    Score: 0.094
  23. Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van Rhee F, Pineda-Roman M, Mohiuddin A, Crowley J, Tricot G. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin Lymphoma Myeloma. 2006 May; 6(6):469-74.
    View in: PubMed
    Score: 0.093
  24. Takebe N, Cheng X, Fandy TE, Srivastava RK, Wu S, Shankar S, Bauer K, Shaughnessy J, Tricot G. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther. 2006 Feb; 5(2):457-66.
    View in: PubMed
    Score: 0.091
  25. Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opin Investig Drugs. 2005 Nov; 14(11):1411-8.
    View in: PubMed
    Score: 0.090
  26. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, Kang SH, Yaccoby S, Najarian K, Richardson P, Sonneveld P, Tricot G. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol. 2005 Oct; 131(1):71-3.
    View in: PubMed
    Score: 0.089
  27. Sherman AC, Simonton S, Latif U, Spohn R, Tricot G. Religious struggle and religious comfort in response to illness: health outcomes among stem cell transplant patients. J Behav Med. 2005 Aug; 28(4):359-67.
    View in: PubMed
    Score: 0.088
  28. Tricot G. Prognostic factors in multiple myeloma. Clin Adv Hematol Oncol. 2005 Mar; 3(3):167-8.
    View in: PubMed
    Score: 0.086
  29. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005 May 15; 105(10):3939-44.
    View in: PubMed
    Score: 0.085
  30. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, Heyman M, Rapoport AP, Badros A, Shaughnessy J, Ross D, Meisenberg B, Tricot G. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res. 2004 Dec 15; 10(24):8301-8.
    View in: PubMed
    Score: 0.084
  31. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, Ashby C, Bauer MA, Hadidi SA, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood Cancer J. 2024 11 06; 14(1):194.
    View in: PubMed
    Score: 0.084
  32. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol. 2004 Sep; 126(5):715-21.
    View in: PubMed
    Score: 0.083
  33. Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Tricot G, Shaughnessy J, Zhan F, Sawyer J, Siegel ER, Zangari M, Barlogie B, van Rhee F. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2024 Nov; 99(11):2222-2224.
    View in: PubMed
    Score: 0.082
  34. Fassas AB, Tricot G. Chromosome 13 deletion/hypodiploidy and prognosis in multiple myeloma patients. Leuk Lymphoma. 2004 Jun; 45(6):1083-91.
    View in: PubMed
    Score: 0.081
  35. Fassas AB, Tricot G. Tandem transplants in the treatment of multiple myeloma. Pro. Clin Adv Hematol Oncol. 2004 May; 2(5):303-4.
    View in: PubMed
    Score: 0.081
  36. Tricot G, Barlogie B, Van Rhee F. Treatment advances in multiple myeloma. Br J Haematol. 2004 Apr; 125(1):24-30.
    View in: PubMed
    Score: 0.080
  37. Guo W, Zhan Y, Mery D, Siegel ER, Sun F, Cheng Y, Ashby TC, Zhang Z, Bailey C, Alapat DV, Peng H, Hadidi SA, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood Cancer J. 2024 02 14; 14(1):30.
    View in: PubMed
    Score: 0.080
  38. Al Hadidi S, Ababneh OE, Schinke CD, Thanendrarajan S, Bailey C, Smith R, Panozzo S, Alapat D, Cottler-Fox M, Tricot G, Shaughnessy JD, Zhan F, Sawyer J, Barlogie B, Zangari M, van Rhee F. Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up. Blood Adv. 2024 02 13; 8(3):703-707.
    View in: PubMed
    Score: 0.080
  39. Fassas AB, Ward S, Muwalla F, Van Hemert R, Schluterman K, Harik S, Tricot G. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004 Feb; 45(2):291-300.
    View in: PubMed
    Score: 0.079
  40. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.
    View in: PubMed
    Score: 0.079
  41. Sun F, Cheng Y, Chen JR, Wanchai V, Mery DE, Xu H, Gai D, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. 2024 01 02; 134(1).
    View in: PubMed
    Score: 0.079
  42. Guo W, Zhan A, Mery DE, Munshi MN, Makhoul O, Baily C, Zangari M, Tricot G, Peng H, Shaughnessy JD. Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS. Blood Adv. 2023 11 14; 7(21):6676-6684.
    View in: PubMed
    Score: 0.078
  43. Fassas AB, Barlogie B, Ward S, Jagannath S, Vesole D, Mattox S, Siegel D, Muwalla F, Zangari M, Anaissie E, Rhee FV, Thertulien R, Lee CK, Desikan R, Arzumanian V, McCoy J, Tricot G. Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience. Br J Haematol. 2003 Nov; 123(3):484-9.
    View in: PubMed
    Score: 0.078
  44. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 10 17; 4(10):101214.
    View in: PubMed
    Score: 0.078
  45. Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15; 21(14):2732-9.
    View in: PubMed
    Score: 0.076
  46. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 06 29; 16(1):70.
    View in: PubMed
    Score: 0.076
  47. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, Fassas A, Van Rhee F, Talamo G, Lee CK, Tricot G. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma. 2003 Jun; 4(1):32-5.
    View in: PubMed
    Score: 0.076
  48. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G. The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost. 2003 Jun; 29(3):275-82.
    View in: PubMed
    Score: 0.076
  49. Fassas AB, Van Rhee F, Tricot G. Predicting long-term survival in multiple myeloma patients following autotransplants. Leuk Lymphoma. 2003 May; 44(5):749-58.
    View in: PubMed
    Score: 0.075
  50. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003 Feb; 120(3):413-23.
    View in: PubMed
    Score: 0.074
  51. Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003 Jan; 31(1):73-80.
    View in: PubMed
    Score: 0.074
  52. Barill?-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G. Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program. 2003; 248-78.
    View in: PubMed
    Score: 0.074
  53. Barlogie B, Shaughnessy J, Zangari M, Tricot G. High-dose therapy and immunomodulatory drugs in multiple myeloma. Semin Oncol. 2002 Dec; 29(6 Suppl 17):26-33.
    View in: PubMed
    Score: 0.073
  54. Fassas AB, Spencer T, Desikan R, Zangari M, Anaissie E, Barlogie B, Tricot G. Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol. 2002 Oct; 119(1):164-8.
    View in: PubMed
    Score: 0.072
  55. Gai D, Chen JR, Stewart JP, Nookaew I, Habelhah H, Ashby C, Sun F, Cheng Y, Li C, Xu H, Peng B, Garg TK, Schinke C, Thanendrarajan S, Zangari M, Chen F, Barlogie B, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation. J Clin Invest. 2022 09 15; 132(18).
    View in: PubMed
    Score: 0.072
  56. Fassas AB, Spencer T, Sawyer J, Zangari M, Lee CK, Anaissie E, Muwalla F, Morris C, Barlogie B, Tricot G. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol. 2002 Sep; 118(4):1041-7.
    View in: PubMed
    Score: 0.072
  57. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002 Aug 15; 100(4):1168-71.
    View in: PubMed
    Score: 0.072
  58. Tricot GJ. New insights into role of microenvironment in multiple myeloma. Int J Hematol. 2002 Aug; 76 Suppl 1:334-6.
    View in: PubMed
    Score: 0.072
  59. Alqazaqi R, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy J, Zhan F, Tricot G, van Rhee F, Al Hadidi S. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA Netw Open. 2022 08 01; 5(8):e2228877.
    View in: PubMed
    Score: 0.072
  60. Badros A, Morris C, Zangari M, Barlogie B, Tricot G. Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia. Leuk Lymphoma. 2002 Jun; 43(6):1267-71.
    View in: PubMed
    Score: 0.071
  61. Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med. 2002 Apr 01; 112(5):412-3.
    View in: PubMed
    Score: 0.070
  62. Fassas AB, Muwalla F, Berryman T, Benramdane R, Joseph L, Anaissie E, Sethi R, Desikan R, Siegel D, Badros A, Toor A, Zangari M, Morris C, Angtuaco E, Mathew S, Wilson C, Hough A, Harik S, Barlogie B, Tricot G. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002 Apr; 117(1):103-8.
    View in: PubMed
    Score: 0.070
  63. Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002 Mar 01; 20(5):1295-303.
    View in: PubMed
    Score: 0.069
  64. Mohan M, Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, Roy A, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2022 02 08; 6(3):808-817.
    View in: PubMed
    Score: 0.069
  65. Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, Badros A, Zangari M, Munshi N, Anaissie E, Toor A, Barlogie B. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002 Jan; 116(1):211-7.
    View in: PubMed
    Score: 0.069
  66. Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 12 01; 106(12):3215-3218.
    View in: PubMed
    Score: 0.068
  67. Li C, Xia J, Franqui-Machin R, Chen F, He Y, Ashby TC, Teng F, Xu H, Liu D, Gai D, Johnson SK, van Rhee F, Janz S, Shaughnessy JD, Tricot G, Frech I, Zhan F. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 2021 07 15; 131(14).
    View in: PubMed
    Score: 0.067
  68. Mohan M, Szabo A, Yarlagadda N, Gundarlapalli S, Thanendrarajan S, Kendrick S, Schinke C, Alapat D, Sawyer J, Tian E, Tricot G, van Rhee F, Zangari M. Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma. Am J Hematol. 2021 09 01; 96(9):E341-E344.
    View in: PubMed
    Score: 0.066
  69. Gao M, Bai H, Jethava Y, Wu Y, Zhu Y, Yang Y, Xia J, Cao H, Franqui-Machin R, Nadiminti K, Thomas GS, Salama ME, Altevogt P, Bishop G, Tomasson M, Janz S, Shi J, Chen L, Frech I, Tricot G, Zhan F. Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. J Natl Cancer Inst. 2020 05 01; 112(5):507-515.
    View in: PubMed
    Score: 0.061
  70. Yu T, Du C, Ma X, Sui W, Yu Z, Liu L, Zhao L, Li Z, Xu J, Wei X, Zhou W, Deng S, Zou D, An G, Tai YT, Tricot G, Anderson KC, Qiu L, Zhan F, Hao M. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Mol Cancer Res. 2020 07; 18(7):1063-1073.
    View in: PubMed
    Score: 0.061
  71. Wang Y, Huang J, Li B, Xue H, Tricot G, Hu L, Xu Z, Sun X, Chang S, Gao L, Tao Y, Xu H, Xie Y, Xiao W, Yu D, Kong Y, Chen G, Sun X, Lian F, Zhang N, Wu X, Mao Z, Zhan F, Zhu W, Shi J. A Small-Molecule Inhibitor Targeting TRIP13 Suppresses Multiple Myeloma Progression. Cancer Res. 2020 02 01; 80(3):536-548.
    View in: PubMed
    Score: 0.059
  72. Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. BMC Cancer. 2018 Nov 21; 18(1):1152.
    View in: PubMed
    Score: 0.055
  73. De Roos AJ, Spinelli J, Brown EB, Atanackovic D, Baris D, Bernstein L, Bhatti P, Camp NJ, Chiu BC, Clavel J, Cozen W, De Sanjos? S, Dosman JA, Hofmann JN, McLaughlin JR, Miligi L, Monnereau A, Orsi L, Purdue MP, Schinasi LH, Tricot GJ, Wang SS, Zhang Y, Birmann BM, Cocco P. Pooled study of occupational exposure to aromatic hydrocarbon solvents and risk of multiple myeloma. Occup Environ Med. 2018 11; 75(11):798-806.
    View in: PubMed
    Score: 0.054
  74. Franqui-Machin R, Hao M, Bai H, Gu Z, Zhan X, Habelhah H, Jethava Y, Qiu L, Frech I, Tricot G, Zhan F. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest. 2018 07 02; 128(7):2877-2893.
    View in: PubMed
    Score: 0.054
  75. Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S. Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. Blood Cancer J. 2018 02 15; 8(2):22.
    View in: PubMed
    Score: 0.053
  76. Birmann BM, Andreotti G, De Roos AJ, Camp NJ, Chiu BCH, Spinelli JJ, Becker N, Benhaim-Luzon V, Bhatti P, Boffetta P, Brennan P, Brown EE, Cocco P, Costas L, Cozen W, de Sanjos? S, Foretov? L, Giles GG, Maynadi? M, Moysich K, Nieters A, Staines A, Tricot G, Weisenburger D, Zhang Y, Baris D, Purdue MP. Young Adult and Usual Adult Body Mass Index and Multiple Myeloma Risk: A Pooled Analysis in the International Multiple Myeloma Consortium (IMMC). Cancer Epidemiol Biomarkers Prev. 2017 06; 26(6):876-885.
    View in: PubMed
    Score: 0.049
  77. Gu Z, Xia J, Xu H, Frech I, Tricot G, Zhan F. NEK2 Promotes Aerobic Glycolysis in Multiple Myeloma Through Regulating Splicing of Pyruvate Kinase. J Hematol Oncol. 2017 01 13; 10(1):17.
    View in: PubMed
    Score: 0.049
  78. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618.
    View in: PubMed
    Score: 0.047
  79. Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, Miligi L, Beane Freeman LE, de Sanjose S, Bernstein L, Monnereau A, Clavel J, Tricot GJ, Atanackovic D, Cocco P, Orsi L, Dosman JA, McLaughlin JR, Purdue MP, Cozen W, Spinelli JJ, de Roos AJ. Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium. Br J Haematol. 2016 Oct; 175(1):87-101.
    View in: PubMed
    Score: 0.047
  80. Ramani VC, Zhan F, He J, Barbieri P, Noseda A, Tricot G, Sanderson RD. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma. Oncotarget. 2016 Jan 12; 7(2):1598-607.
    View in: PubMed
    Score: 0.045
  81. Kelly KR, Espitia CM, Zhao W, Wendlandt E, Tricot G, Zhan F, Carew JS, Nawrocki ST. Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus. Oncotarget. 2015 Dec 01; 6(38):41275-89.
    View in: PubMed
    Score: 0.045
  82. Costas L, Lambert BH, Birmann BM, Moysich KB, De Roos AJ, Hofmann JN, Baris D, Wang SS, Camp NJ, Tricot G, Atanackovic D, Brennan P, Cocco P, Nieters A, Becker N, Maynadi? M, Foretov? L, Boffetta P, Staines A, Brown EE, de Sanjos? S. A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Consortium. Cancer Epidemiol Biomarkers Prev. 2016 Jan; 25(1):217-21.
    View in: PubMed
    Score: 0.045
  83. Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma. Clin Cancer Res. 2015 Dec 15; 21(24):5532-42.
    View in: PubMed
    Score: 0.044
  84. Gu Z, Wang H, Xia J, Yang Y, Jin Z, Xu H, Shi J, De Domenico I, Tricot G, Zhan F. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation. Cancer Res. 2015 Jun 01; 75(11):2211-21.
    View in: PubMed
    Score: 0.043
  85. Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F. Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res. 2015 Feb 01; 75(3):594-604.
    View in: PubMed
    Score: 0.042
  86. Andreotti G, Birmann BM, Cozen W, De Roos AJ, Chiu BC, Costas L, de Sanjos? S, Moysich K, Camp NJ, Spinelli JJ, Pahwa P, Dosman JA, McLaughlin JR, Boffetta P, Staines A, Weisenburger D, Benhaim-Luzon V, Brennan P, Costantini AS, Miligi L, Campagna M, Nieters A, Becker N, Maynadi? M, Foretov? L, Zheng T, Tricot G, Milliken K, Krzystan J, Steplowski E, Baris D, Purdue MP. A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium. Cancer Epidemiol Biomarkers Prev. 2015 Mar; 24(3):631-4.
    View in: PubMed
    Score: 0.042
  87. Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F. NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. Oncotarget. 2014 Dec 15; 5(23):11986-97.
    View in: PubMed
    Score: 0.042
  88. Gu Z, Zhou W, Huang J, Yang Y, Wendlandt E, Xu H, He X, Tricot G, Zhan F. Nek2 is a novel regulator of B cell development and immunological response. Biomed Res Int. 2014; 2014:621082.
    View in: PubMed
    Score: 0.042
  89. Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE. Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1949-57.
    View in: PubMed
    Score: 0.041
  90. Long G, Waller EK, Gregurek S, Tricot G, Marschner S, Bill J. Evaluation of the spectra Optia? mononuclear cell collection procedure in multiple myeloma patients. J Clin Apher. 2015 Feb; 30(1):1-7.
    View in: PubMed
    Score: 0.041
  91. Zangari M, Berno T, Yang Y, Zeng M, Xu H, Pappas L, Tricot G, Kamalakar A, Yoon D, Suva LJ. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors. Bone. 2014 Apr; 61:39-43.
    View in: PubMed
    Score: 0.039
  92. Andreotti G, Birmann B, De Roos AJ, Spinelli J, Cozen W, Camp NJ, Moysich K, Chiu B, Steplowski E, Krzystan J, Boffetta P, Benhaim-Luzon V, Brennan P, de Sanjos? S, Costas L, Costantini AS, Miligi L, Cocco P, Becker N, Foretov? L, Maynadi? M, Nieters A, Staines A, Tricot G, Milliken K, Weisenburger D, Zheng T, Baris D, Purdue MP. A pooled analysis of alcohol consumption and risk of multiple myeloma in the international multiple myeloma consortium. Cancer Epidemiol Biomarkers Prev. 2013 Sep; 22(9):1620-7.
    View in: PubMed
    Score: 0.038
  93. Veitonm?ki N, Hansson M, Zhan F, Sundberg A, L?fstedt T, Ljungars A, Li ZC, Martinsson-Niskanen T, Zeng M, Yang Y, Danielsson L, Kovacek M, Lundqvist A, M?rtensson L, Teige I, Tricot G, Frend?us B. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15; 23(4):502-15.
    View in: PubMed
    Score: 0.038
  94. Zhou W, Yang Y, Xia J, Wang H, Salama ME, Xiong W, Xu H, Shetty S, Chen T, Zeng Z, Shi L, Zangari M, Miles R, Bearss D, Tricot G, Zhan F. NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell. 2013 Jan 14; 23(1):48-62.
    View in: PubMed
    Score: 0.037
  95. Zangari M, Berno T, Zhan F, Tricot G, Fink L. Mechanisms of thrombosis in paraproteinemias: the effects of immunomodulatory drugs. Semin Thromb Hemost. 2012 Nov; 38(8):768-79.
    View in: PubMed
    Score: 0.036
  96. Kim JH, Goulston C, Sanders S, Lampas M, Zangari M, Tricot G, Hanson KE. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1753-8.
    View in: PubMed
    Score: 0.035
  97. Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD, Nair BP, Bellamy WT, Epstein J, Barlogie B, van Rhee F. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012 Sep; 97(9):1348-56.
    View in: PubMed
    Score: 0.035
  98. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83.
    View in: PubMed
    Score: 0.034
  99. Zangari M, Berno T, Zhan F, Boucher KM, Tricot G, Fink L. Activated protein C resistance as measured by residual factor V after Russell's viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls. Blood Coagul Fibrinolysis. 2011 Jul; 22(5):420-3.
    View in: PubMed
    Score: 0.033
  100. Wu X, Shi J, Wu Y, Tao Y, Hou J, Meng X, Hu X, Han Y, Jiang W, Tang S, Zangari M, Tricot G, Zhan F. Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther. 2010 Dec 01; 10(11):1201-14.
    View in: PubMed
    Score: 0.032
  101. Zangari M, Zhan F, Tricot G. Bone and paraproteinemias. Curr Opin Support Palliat Care. 2010 Sep; 4(3):195-9.
    View in: PubMed
    Score: 0.031
  102. Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol. 2010 Sep; 150(5):554-64.
    View in: PubMed
    Score: 0.031
  103. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, Zhan F. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget. 2010 May; 1(1):22-33.
    View in: PubMed
    Score: 0.031
  104. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 01; 28(1):132-5.
    View in: PubMed
    Score: 0.030
  105. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):908-42.
    View in: PubMed
    Score: 0.029
  106. Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis. 2009 Jul; 20(5):337-9.
    View in: PubMed
    Score: 0.029
  107. Wang S, Tricot G, Shi L, Xiong W, Zeng Z, Xu H, Zangari M, Barlogie B, Shaughnessy JD, Zhan F. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood. 2009 Jul 16; 114(3):600-7.
    View in: PubMed
    Score: 0.029
  108. Prince HM, H?nemann D, Spencer A, Rizzieri DA, Stadtmauer EA, Roberts AW, Bahlis N, Tricot G, Bell B, Demarini DJ, Benjamin Suttle A, Baker KL, Pandite LN. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood. 2009 May 07; 113(19):4819-20.
    View in: PubMed
    Score: 0.029
  109. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD, Barlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008 Dec; 143(5):641-53.
    View in: PubMed
    Score: 0.027
  110. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008 Oct 15; 112(8):3115-21.
    View in: PubMed
    Score: 0.027
  111. Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F, Tricot G, Crowley J. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients. Cancer. 2008 Apr 15; 112(8):1754-64.
    View in: PubMed
    Score: 0.027
  112. Pineda-Roman M, Zangari M, Haessler J, Anaissie E, Tricot G, van Rhee F, Crowley J, Shaughnessy JD, Barlogie B. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol. 2008 Mar; 140(6):625-34.
    View in: PubMed
    Score: 0.026
  113. Haessler J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van Rhee F, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res. 2007 Dec 01; 13(23):7073-9.
    View in: PubMed
    Score: 0.026
  114. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007 Nov-Dec; 30(8):847-54.
    View in: PubMed
    Score: 0.026
  115. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD, Barlogie B, van Rhee F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008 Feb 01; 111(3):1309-17.
    View in: PubMed
    Score: 0.026
  116. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood. 2008 Jan 01; 111(1):94-100.
    View in: PubMed
    Score: 0.026
  117. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007 Jul; 138(2):176-85.
    View in: PubMed
    Score: 0.025
  118. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007 Aug 01; 110(3):827-32.
    View in: PubMed
    Score: 0.025
  119. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, Epstein J, van Hemert R, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van Rhee F, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol. 2007 Mar 20; 25(9):1121-8.
    View in: PubMed
    Score: 0.024
  120. Pineda-Roman M, Tricot G. High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction. Contrib Nephrol. 2007; 153:182-94.
    View in: PubMed
    Score: 0.024
  121. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007 Mar 15; 109(6):2276-84.
    View in: PubMed
    Score: 0.024
  122. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007 Feb 15; 109(4):1692-700.
    View in: PubMed
    Score: 0.024
  123. Szmania S, Tricot G, van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leuk Lymphoma. 2006 Oct; 47(10):2037-48.
    View in: PubMed
    Score: 0.024
  124. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol. 2006 Oct; 135(2):158-64.
    View in: PubMed
    Score: 0.024
  125. Elice F, Fink L, Tricot G, Barlogie B, Zangari M. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol. 2006 Aug; 134(4):399-405.
    View in: PubMed
    Score: 0.024
  126. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD. The molecular classification of multiple myeloma. Blood. 2006 Sep 15; 108(6):2020-8.
    View in: PubMed
    Score: 0.023
  127. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 2006 Sep 01; 108(5):1724-32.
    View in: PubMed
    Score: 0.023
  128. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 09; 354(10):1021-30.
    View in: PubMed
    Score: 0.023
  129. Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 2006 Feb; 91(2):192-9.
    View in: PubMed
    Score: 0.023
  130. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006 Apr 01; 107(7):2633-8.
    View in: PubMed
    Score: 0.023
  131. Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G, van Rhee F. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma. Cancer Res. 2005 Nov 01; 65(21):10041-9.
    View in: PubMed
    Score: 0.022
  132. Talamo G, Angtuaco E, Walker RC, Dong L, Miceli MH, Zangari M, Tricot G, Barlogie B, Anaissie E. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy. J Clin Oncol. 2005 Aug 01; 23(22):5217-23.
    View in: PubMed
    Score: 0.022
  133. Sawyer JR, Tricot G, Lukacs JL, Binz RL, Tian E, Barlogie B, Shaughnessy J. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer. 2005 Jan; 42(1):95-106.
    View in: PubMed
    Score: 0.021
  134. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004 Apr; 121(4):482-8.
    View in: PubMed
    Score: 0.020
  135. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. Treatment of multiple myeloma. Blood. 2004 Jan 01; 103(1):20-32.
    View in: PubMed
    Score: 0.019
  136. Jacobson J, Barlogie B, Shaughnessy J, Drach J, Tricot G, Fassas A, Zangari M, Giroux D, Crowley J, Hough A, Sawyer J. MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants. Br J Haematol. 2003 Aug; 122(3):430-40.
    View in: PubMed
    Score: 0.019
  137. Desikan R, Barlogie B, Sethi R, Toor A, Spoon D, Angtuaco E, Vanhemert R, VijayaGopal A, Singhal S, Mehta J, Jagannath S, Munshi N, Zangari M, Fassas A, Tricot G, Anaissie E. Infection--an underappreciated cause of bone pain in multiple myeloma. Br J Haematol. 2003 Mar; 120(6):1047-50.
    View in: PubMed
    Score: 0.019
  138. Shaughnessy J, Jacobson J, Sawyer J, McCoy J, Fassas A, Zhan F, Bumm K, Epstein J, Anaissie E, Jagannath S, Vesole D, Siegel D, Desikan R, Munshi N, Badros A, Tian E, Zangari M, Tricot G, Crowley J, Barlogie B. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood. 2003 May 15; 101(10):3849-56.
    View in: PubMed
    Score: 0.018
  139. Shaughnessy J, Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, Anaissie E, Zangari M, Fassas A, Muwalla F, Morris C, Barlogie B. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol. 2003 Jan; 120(1):44-52.
    View in: PubMed
    Score: 0.018
  140. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003; 4(6):379-98.
    View in: PubMed
    Score: 0.018
  141. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002 May 01; 99(9):3280-5.
    View in: PubMed
    Score: 0.018
  142. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002 Mar 01; 99(5):1745-57.
    View in: PubMed
    Score: 0.017
  143. Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N, Barlogie B, Cottler-Fox M. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002 Feb; 42(2):205-9.
    View in: PubMed
    Score: 0.017
  144. Xia J, Xu H, Zhang X, Allamargot C, Coleman KL, Nessler R, Frech I, Tricot G, Zhan F. Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid. EBioMedicine. 2017 Apr; 18:41-49.
    View in: PubMed
    Score: 0.012
  145. Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014 Aug; 59(1-3):188-202.
    View in: PubMed
    Score: 0.010
  146. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
    View in: PubMed
    Score: 0.008
  147. Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist. 2002; 7 Suppl 1:1-13.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.